Centene stock moves after recent performance

Centene (CNC) has drawn investor attention after recent share performance, with the stock showing a 2.5% decline over the past day and an 8.4% fall over the past week.

With the share price at US$39.92 after a 12.7% 1 month share price decline, recent weakness contrasts with a 6.3% 3 month share price gain, while the 1 year total shareholder return of a 31.9% loss suggests momentum has been fading rather than building.

If Centene’s share price movements have you reassessing your watchlist, this could be a moment to broaden your search with 25 healthcare AI stocks as a fresh set of healthcare ideas.

With Centene posting a recent loss, yet trading around US$39.92 and sitting at a sizeable discount to one estimate of intrinsic value, investors may be wondering whether this weakness represents a potential opening or whether the market is already pricing in all available information.

Most Popular Narrative: 2.9% Undervalued

Centene’s most followed narrative puts fair value at about $41.12 per share, only slightly above the recent $39.92 close, which keeps attention on the assumptions behind that small gap.

Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses.

Curious what justifies that fair value lift when the share price has fallen over the past year? The narrative leans on specific revenue growth, margin recovery and future valuation assumptions that are far from conservative on every line. Want to see exactly how those moving parts add up.

Result: Fair Value of $41.12 (UNDERVALUED)

However, this narrative could be knocked off course if Medicaid rate decisions fall short of expectations or if medical and specialty drug costs run hotter than projected.

Build Your Own Centene Narrative

If parts of this story do not sit right with you, or you would rather lean on your own work, you can pull the same data, stress test the assumptions and build a custom view in just a few minutes with Do it your way.

A great starting point for your Centene research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If this Centene review has sharpened your thinking, do not stop here. Put that focus to work and line up a few more quality candidates.

• Target potential value opportunities by scanning our list of 55 high quality undervalued stocks that match strong fundamentals with priced-in pessimism.
• Strengthen the core of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (46 results) that aim to keep financial risk in check.
• Get ahead of the crowd by checking our screener containing 25 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.